VSee Health selected for NIH-funded stroke recovery telerehab trial

SAN JOSE, Calif. - VSee Health, Inc. (NASDAQ:VSEE), a $17.18 million market cap telehealth company whose shares have declined over 90% in the past year, has been chosen to support a National Institutes of Health-funded Phase 3 clinical trial studying stroke recovery telerehabilitation based out of UCLA, according to a press release statement.

The trial will involve 29 hospitals and 202 patients, evaluating the outcomes of adding six weeks of gamified, home-based telerehabilitation to improve arm functionality in stroke survivors. The study aims to reduce costs related to transportation, caregiver burdens, and hospital readmissions. InvestingPro analysis indicates the company maintains a healthy 72.48% gross margin, though it faces challenges with cash burn and short-term obligations.

Dr. Steven Cramer, professor of neurology at UCLA and co-principal investigator, said the Phase 3 milestone "has been twelve years in the making" and noted VSee Health's HIPAA-compliant platform has been "instrumental in ensuring secure, seamless delivery" of interventions.

The company previously supported Phase 1 and Phase 2 of this neurology study. Enrollment for the clinical trial is scheduled to begin in Q3 2025.

The study will combine independent and remote therapist-supervised games and exercises delivered through VSee's platform to address barriers such as limited access to physical therapy clinics and patient motivation issues.

If successful, the trial could potentially open opportunities for Medicare and private payer reimbursement in the stroke rehabilitation market, where telehealth solutions may offer advantages in patient adherence and cost reduction compared to traditional physical therapy.

VSee Health provides a customizable HIPAA-compliant digital health platform and services designed to deliver integrated healthcare remotely.

In other recent news, VSee Health, Inc. has received a notice from Nasdaq due to non-compliance with filing requirements, as it failed to submit its quarterly and annual financial reports on time. The company has a 60-day window to present a compliance plan, potentially extending to October 13, 2025, if accepted. VSee Health attributes the delay to the need for additional time and resources following a merger in June 2024. Despite the notice, VSee Health's securities continue to be listed and traded on Nasdaq without immediate impact. The company has also launched Project MAMA, a telehealth initiative in the Philippines, aimed at reducing maternal mortality rates through remote consultations and AI technology. Additionally, VSee Health has unveiled a Telenursing Robotics solution to automate routine nursing tasks, potentially reducing hospital labor costs by 3-5%. Clinical pilot programs are being initiated to measure cost savings and workflow improvements. These developments highlight VSee Health's ongoing efforts in digital health innovation and compliance with Nasdaq requirements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.